<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunotherapy with therapeutic idiotype vaccines offers promise for treatment of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, identification of novel immunogenic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-associated antigens that are universally expressed is necessary to overcome the barriers of patient-specific idiotype vaccines </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we determined whether T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1 (TCL1) oncoprotein encoded by the TCL1 gene could be a target for immunotherapy of B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We show that TCL1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein are selectively expressed in <z:mpath ids='MPATH_458'>normal</z:mpath> B cells but markedly hyperexpressed in multiple human B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, including follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and splenic marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrated that TCL1-specific CD8(+) T cells can be generated from HLA-A*0201 (HLA-A2)(+) <z:mpath ids='MPATH_458'>normal</z:mpath> donors and identified TCL1(71-78) (LLPIMWQL) as the minimal <z:chebi fb="0" ids="53000">epitope</z:chebi> recognized by these T cells </plain></SENT>
<SENT sid="5" pm="."><plain>More importantly, TCL1(71-78) <z:chebi fb="7" ids="16670">peptide</z:chebi>-specific T cells were present in the peripheral blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-infiltrating lymphocytes of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients, could be expanded in vitro, and lysed autologous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells but not <z:mpath ids='MPATH_458'>normal</z:mpath> B cells in an HLA-A2-restricted manner </plain></SENT>
<SENT sid="6" pm="."><plain>Our results suggest that TCL1 is naturally processed and presented on the surface of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells for recognition by cytotoxic T cells and can serve as a novel target for development of immunotherapeutic strategies against common B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>